adalimumab
Humira (adalimumab) is a fully human monoclonal antibody from AbbVie that neutralises tumour necrosis factor alpha (TNF-alpha), a key driver of inflammatory disease. It is used across several chronic inflammatory conditions, including rheumatoid arthritis, Crohn disease, ulcerative colitis, plaque psoriasis and uveitis.
This page is based on FDA prescribing information and the EMA medicine record for adalimumab; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
In inflammatory disease, TNF-alpha acts like an alarm bell that immune cells keep ringing, summoning more inflammation to the joint, gut or skin. Adalimumab is a sponge shaped exactly for that bell - it soaks up the signal before it can be heard, so the alarm dies down and irritated tissue gets a chance to settle.
In simple terms
Adalimumab is a biologic antibody that targets TNF-alpha, one of the main chemical messengers of inflammation. In conditions like rheumatoid arthritis, psoriasis and Crohn disease, too much TNF-alpha keeps the immune system attacking the body's own tissues. Adalimumab binds TNF-alpha and neutralises it, which calms the inflammatory cascade, reduces symptoms and can slow structural damage.
In depth
Adalimumab is a recombinant fully human IgG1 monoclonal antibody that binds soluble and membrane-bound TNF-alpha with high affinity, preventing engagement of TNFR1 and TNFR2. It does not bind lymphotoxin alpha. By blocking TNF signalling it downregulates downstream cytokines such as IL-1 and IL-6, reduces leukocyte migration and adhesion molecule expression, and may induce complement-mediated lysis or apoptosis of cells expressing membrane TNF.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How adalimumab works
- In conditions like rheumatoid arthritis, psoriasis and Crohn disease, too much TNF-alpha keeps the immune system attacking the body's own tissues.
- Adalimumab is a recombinant fully human IgG1 monoclonal antibody that binds soluble and membrane-bound TNF-alpha with high affinity, preventing engagement of TNFR1 and TNFR2.
- It does not bind lymphotoxin alpha.
- By blocking TNF signalling it downregulates downstream cytokines such as IL-1 and IL-6, reduces leukocyte migration and adhesion molecule expression, and may induce complement-mediated lysis or apoptosis of cells expressing membrane TNF.
Target: Tumour necrosis factor alpha (TNF-alpha)
A pro-inflammatory cytokine that recruits immune cells and sustains chronic inflammation; in diseases such as rheumatoid arthritis and Crohn disease it is overproduced and keeps tissue damage going.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- Reducing signs and symptoms, inhibiting structural damage progression and improving physical function in adults with moderately to severely active rheumatoid arthritis
- Moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
- Active psoriatic arthritis in adults
- Active ankylosing spondylitis in adults
- Moderately to severely active Crohn disease in adults and pediatric patients 6 years and older
- Moderately to severely active ulcerative colitis in adults and pediatric patients 5 years and older
- Moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
- Moderate to severe hidradenitis suppurativa in patients 12 years of age and older
- Non-infectious intermediate, posterior and panuveitis in patients 2 years of age and older
Approved uses in European Union
EMA- Rheumatoid arthritis, in combination with methotrexate (or as monotherapy when methotrexate is inappropriate), for adults with moderately to severely active disease
- Polyarticular juvenile idiopathic arthritis in children and adolescents from 2 years of age
- Psoriatic arthritis in adults with active and progressive disease
- Axial spondyloarthritis, including severe active ankylosing spondylitis and non-radiographic axial spondyloarthritis with objective signs of inflammation
- Moderately to severely active Crohn disease in adults, and in children and adolescents from 6 years of age
- Moderately to severely active ulcerative colitis in adults, and in children and adolescents from 6 years of age
- Moderate to severe chronic plaque psoriasis in adults, and in children and adolescents from 4 years of age
- Moderate to severe hidradenitis suppurativa in adults and adolescents from 12 years of age
- Non-infectious intermediate, posterior and panuveitis in adults, and in children from 2 years of age
Official sources
The statements on this page trace back to these records.
- Humira (adalimumab) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- U.S. Food and Drug Administration: adalimumab prescribing information
U.S. Food and Drug Administration
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.